Welcome to the UPF Digital Repository

A faecal microbiota signature with high specificity for pancreatic cancer

Show simple item record

dc.contributor.author Kartal, Ece
dc.contributor.author Real, Francisco X.
dc.contributor.author Bork, Peer
dc.date.accessioned 2023-02-16T07:09:22Z
dc.date.available 2023-02-16T07:09:22Z
dc.date.issued 2022
dc.identifier.citation Kartal E, Schmidt TSB, Molina-Montes E, Rodríguez-Perales S, Wirbel J, Maistrenko OM, et al. A faecal microbiota signature with high specificity for pancreatic cancer. Gut. 2022 Jul; 71(7): 1359-72. DOI: 10.1136/gutjnl-2021-324755
dc.identifier.issn 0017-5749
dc.identifier.uri http://hdl.handle.net/10230/55801
dc.description.abstract Background: recent evidence suggests a role for the microbiome in pancreatic ductal adenocarcinoma (PDAC) aetiology and progression. Objective: to explore the faecal and salivary microbiota as potential diagnostic biomarkers. Methods: we applied shotgun metagenomic and 16S rRNA amplicon sequencing to samples from a Spanish case-control study (n=136), including 57 cases, 50 controls, and 29 patients with chronic pancreatitis in the discovery phase, and from a German case-control study (n=76), in the validation phase. Results: faecal metagenomic classifiers performed much better than saliva-based classifiers and identified patients with PDAC with an accuracy of up to 0.84 area under the receiver operating characteristic curve (AUROC) based on a set of 27 microbial species, with consistent accuracy across early and late disease stages. Performance further improved to up to 0.94 AUROC when we combined our microbiome-based predictions with serum levels of carbohydrate antigen (CA) 19-9, the only current non-invasive, Food and Drug Administration approved, low specificity PDAC diagnostic biomarker. Furthermore, a microbiota-based classification model confined to PDAC-enriched species was highly disease-specific when validated against 25 publicly available metagenomic study populations for various health conditions (n=5792). Both microbiome-based models had a high prediction accuracy on a German validation population (n=76). Several faecal PDAC marker species were detectable in pancreatic tumour and non-tumour tissue using 16S rRNA sequencing and fluorescence in situ hybridisation. Conclusion: taken together, our results indicate that non-invasive, robust and specific faecal microbiota-based screening for the early detection of PDAC is feasible.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher BMJ Publishing Group
dc.rights This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: http://creativecommons.org/ licenses/by/4.0/.
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title A faecal microbiota signature with high specificity for pancreatic cancer
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1136/gutjnl-2021-324755
dc.subject.keyword Cancer prevention
dc.subject.keyword Intestinal microbiology
dc.subject.keyword Pancreatic cancer
dc.subject.keyword Pancreatic tumours
dc.subject.keyword Screening
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


In collaboration with Compliant to Partaking